81 related articles for article (PubMed ID: 22197354)
1. Urethra sparing - potential of combined Nickel-Titanium stent and intensity modulated radiation therapy in prostate cancer.
Thomsen JB; Arp DT; Carl J
Radiother Oncol; 2012 May; 103(2):256-60. PubMed ID: 22197354
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy.
Carl J; Lund B; Larsen EH; Nielsen J
Radiother Oncol; 2006 Feb; 78(2):199-206. PubMed ID: 16413623
[TBL] [Abstract][Full Text] [Related]
3. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases.
Zhang P; Happersett L; Hunt M; Jackson A; Zelefsky M; Mageras G
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1456-62. PubMed ID: 19540062
[TBL] [Abstract][Full Text] [Related]
4. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy.
Yoon M; Ahn SH; Kim J; Shin DH; Park SY; Lee SB; Shin KH; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1477-85. PubMed ID: 19879701
[TBL] [Abstract][Full Text] [Related]
6. Patterns of practice in intensity-modulated radiation therapy and image-guided radiation therapy for prostate cancer in Japan.
Nakamura K; Akimoto T; Mizowaki T; Hatano K; Kodaira T; Nakamura N; Kozuka T; Shikama N; Kagami Y
Jpn J Clin Oncol; 2012 Jan; 42(1):53-7. PubMed ID: 22131339
[TBL] [Abstract][Full Text] [Related]
7. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
[TBL] [Abstract][Full Text] [Related]
8. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
9. A new lung stent tested as fiducial marker in a porcine model.
Carl J; Nielsen J; Nielsen MS; Zepernick PR; Kjaergaard B; Jensen HK
Radiother Oncol; 2012 Feb; 102(2):297-302. PubMed ID: 22192480
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
12. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation in prostate cancer using intensity modulated neutron radiotherapy.
Snyder M; Joiner MC; Konski A; Bossenberger T; Burmeister J
Radiother Oncol; 2011 May; 99(2):201-6. PubMed ID: 21620496
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
Lee EK; Fox T; Crocker I
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
[TBL] [Abstract][Full Text] [Related]
16. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy.
Smeenk RJ; van Lin EN; van Kollenburg P; Kunze-Busch M; Kaanders JH
Radiother Oncol; 2009 Oct; 93(1):131-6. PubMed ID: 19523704
[TBL] [Abstract][Full Text] [Related]
17. Experience-based quality control of clinical intensity-modulated radiotherapy planning.
Moore KL; Brame RS; Low DA; Mutic S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):545-51. PubMed ID: 21277097
[TBL] [Abstract][Full Text] [Related]
18. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
